Navigation Links
Drug-Eluting Stents Outperform Bare Stents in Heart Attack
Date:3/30/2008

Anti-clotting drug tirofiban also edges abciximab

CHICAGO, March 30 /PRNewswire/ -- New evidence from a large randomized study is answering important questions about the best approach to percutaneous coronary intervention (PCI) in patients with a type of heart attack known as ST-segment-elevation myocardial infarction (STEMI). In the study, drug-eluting stents outperformed bare-metal stents, and high-dose tirofiban, an anti-clotting medication, proved to be equally effective and have fewer side effects than the catheter lab standard, abciximab.

The study is being reported today in a Late-Breaking Clinical Trials session at the SCAI Annual Scientific Sessions in Partnership with ACC i2 Summit (SCAI-ACCi2) in Chicago. SCAI-ACCi2 is a scientific meeting for practicing cardiovascular interventionalists sponsored by the Society for Cardiovascular Angiography and Interventions (SCAI) in partnership with the American College of Cardiology (ACC). This study is also being simultaneously published online in JAMA: Journal of the American Medical Association.

"These findings may provide a robust scientific rationale for high-dose tirofiban as an alternative to abciximab in patients with STEMI," said Marco Valgimigli, MD, PhD, a cardiologist at the Cardiovascular Institute, Azienda Opedaliera Universitaria di Ferrara, Ferrara, Italy. "In addition, at mid-term follow-up our study did not confirm some of the safety concerns over the use of drug-eluting stents in patients with myocardial infarction. These findings are very reassuring, though we need long-term follow-up to rule out the possibility of late adverse events."

Drug-eluting stents -- which not only prop open the coronary arteries but slowly release medication that prevents re-narrowing of the arteries with scar tissue, or restenosis -- are widely used when PCI is performed for stable coronary artery disease. But many cardiologists use bare-metal stents when treating patients wit
'/>"/>

SOURCE SCAI-ACCi2
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
2. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
3. OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) has Lower MACE Rate than TAXUS(R) and CYPHER(R) Stents in Clinical Trial
4. Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
5. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
6. Medifast Outperforms American Diabetes Association Diet by Twice the Weight Loss According to Published Study
7. BRAVE-3 Questions Value of Abciximab in PCI for Heart Attack
8. Stem Cell Research Provides Medical Breakthrough to Repair Heart Cell Damage Created by a Heart Attack
9. DuraHeart(TM) LVAS Receives Conditional Approval for US Pivotal Trial
10. American Heart Association Journal Report: Reducing Kids Salt Intake May Lower Soft Drink Consumption, Reducing Obesity, High Blood Pressure and Later Health Risks
11. Boston Scientific Announces CE Mark Approval for New Devices to Treat Heart Failure and Sudden Cardiac Death
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Utah , Aug. 28, 2015  Today, in ... Prevention,s (CDC) Contact Lens Health Week, 1-800 Contacts is ... has found that contact lens wearers who do not ... greatest risk for eye infections. Most ... their lenses, but a clean lens case is sometimes ...
(Date:8/28/2015)... , Aug. 28, 2015 ... the addition of the "Investigation Report on China,s ... Developed by Novartis, ranibizumab was approved by CFDA ... 2012. Currently, only Lucentis, a product of Novartis, is ... as the first self- developed drug for the treatment ...
(Date:8/28/2015)... Denmark and ATLANTA ... 31, 2015 the US Food and Drug Administration (FDA) cleared ... Depressive Disorder in adult patients who have failed to receive ... TMS is a non-invasive technique for stimulating neural tissue in ... Major Depressive Disorder. The procedure has been proven safe and ...
Breaking Medicine Technology:1-800 Contacts Shares Tips on How to Clean Lens Cases 2Investigation Report on China's Ranibizumab Market, 2012-2019 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 3
... Inc. (NASDAQ: STXS ) announced today ... collaboration with Biosense Webster, Inc. related to Stereotaxis, ... broadest and most committed cooperative agreement around Odyssey ... Stereotaxis has granted Biosense Webster global, non-exclusive rights ...
... Calif., May 5, 2011 NeurogesX, Inc. (NASDAQ: ... novel pain management therapies, announced today that Anthony DiTonno, President ... 10th Annual JMP Securities Research Conference, to be held May ... Annual JMP Securities Research Conference Date : , Monday, ...
Cached Medicine Technology:Stereotaxis and Biosense Webster Announce New Strategic Collaboration 2Stereotaxis and Biosense Webster Announce New Strategic Collaboration 3Stereotaxis and Biosense Webster Announce New Strategic Collaboration 4NeurogesX to Present at 10th Annual JMP Securities Research Conference 2NeurogesX to Present at 10th Annual JMP Securities Research Conference 3
(Date:8/28/2015)... ... August 29, 2015 , ... Rio Salado College ... and the student experience as part of the EDUCAUSE - Next Generation Learning Challenges ... , This is the third Breakthrough Models Incubator hosted by EDUCAUSE and ...
(Date:8/28/2015)... , ... August 28, 2015 , ... ... Malaria Day at the Zoo to celebrate children helping children, a thank you ... congregations throughout West Ohio have contributed to the United Methodist initiative to end ...
(Date:8/28/2015)... ... ... With the goal of furthering music education programs in schools, the “Music ... Fairgrounds in Mendon, IL on May 30th, 2015. Backed once again by Best Drug ... underfunded school districts of Mendon and its neighboring town of Quincy, IL. Best Drug ...
(Date:8/28/2015)... ... August 28, 2015 , ... As reported by Medical Daily on August ... for results that last for two years, the longest of any cellulite reduction system ... looking for a long-lasting, effective solution for their cellulite, according to Dr. Robert Weiss, ...
(Date:8/28/2015)... ... August 28, 2015 , ... Loved ones of a person ... with chemical dependency, may be able to find some hope in the latest ... center for addiction located in Western Michigan. Focusing on several different aspects of ...
Breaking Medicine News(10 mins):Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 3Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 4Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 2Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 3Health News:Best Drug Rehabilitation Interviews Country-Rock Duo Highway Run at the 2015 "Music With A Mission" Benefit Concert 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 2Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 3
... LigoCyte Pharmaceuticals, Inc. announced today that its ... and related gastrointestinal illness collectively known as acute ... "the stomach flu" is one of the most ... and diarrhea afflicting 21 million Americans annually and ...
... -- Hispanic women have a 20 percent greater risk ... according to a new study. Biological differences in ... suggested. "This difference may be associated with a ... Baumgartner, an epidemiology professor at the School of Public ...
... By Mary Brophy Marcus HealthDay Reporter , WEDNESDAY, ... the outer layer of the brain and work its way ... upends long-held beliefs about the nervous system disease. The ... is diagnosed and treated, appear to solidify a theory that,s ...
... and the identification of sensitive biomarkers for early detection and/or ... New work published in the Dec. 7 issue of the ... the development of blood-based DNA markers for ovarian cancer. ... of Southern California in Los Angeles, found that a DNA ...
... Gardner HealthDay Reporter , WEDNESDAY, Dec. 7 ... appears to boost survival in women with certain types ... These preliminary findings regarding the bone-building drug zoledronic acid ... their tumors. The studies are slated for presentation at ...
... By Steven Reinberg HealthDay Reporter , ... are screened for and diagnosed with low-risk prostate cancer, ... National Institutes of Health panel concluded that research on ... prostate cancer is discovered, many men opt for surgery ...
Cached Medicine News:Health News:NEJM publishes study showing LigoCyte's norovirus vaccine demonstrates protection against illness 2Health News:NEJM publishes study showing LigoCyte's norovirus vaccine demonstrates protection against illness 3Health News:NEJM publishes study showing LigoCyte's norovirus vaccine demonstrates protection against illness 4Health News:Hispanic Women More Likely to Die of Breast Cancer 2Health News:MS May Take a Different Pathway Than Previously Thought 2Health News:MS May Take a Different Pathway Than Previously Thought 3Health News:Bone Drugs May Also Battle Breast Cancer, Researchers Say 2Health News:Active Surveillance May Benefit Men With Low-Risk Prostate Cancer 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: